Sector: Life Sciences

Latest content

Five key IP takeaways from Pfizer’s $11.6 billion Biohaven buyout

The industry's biggest deal of 2022 focuses on a small number of patent-protected assets

20 May 2022

Recent Chinese decisions are good news for life sciences patent enforcement

Early patent linkage decisions and a rare interim injunction are hopeful signs for IP owners

19 May 2022

Moderna says US government on the hook to pay any royalties due to mRNA patent owners

The company claims any infringing uses of its vaccine are insulated from liability under compulsory licensing law

17 May 2022

Why ITC actions are an increasingly important tool for life sciences IP owners

US International Trade Commission launches most recent investigation into Botox-style product.

16 May 2022

Legal confusion on essentially derived varieties must be cleared up for the sake of innovation

As gene editing techniques come to the fore in the UK and elsewhere, Joel Smith of Hogan Lovells argues that industry needs clarity on the breeder's exception to plant variety rights

12 May 2022

Why patentees should learn to love multidistrict ANDA suits

Recent US court decisions have had a seismic impact on venue selection in Hatch-Waxman cases. Faegre Drinker’s Alison Baldwin, Eric Friedman and Susan Sharko argue that this can be a favourable development for rights holders and a useful tool for cases in this area of the law

11 May 2022

Unpacking China’s first patent linkage decision

Exclusive analysis based on the full text of the country’s first civil patent linkage judgment reveals how the Beijing IP Court handled the case and why the generic company prevailed

10 May 2022

GSK case shows US authorities mean business on biotech trade secrets

Rights owners have enjoyed success in recent life sciences know-how misappropriation disputes

06 May 2022

WTO to push for greater covid-19 compulsory licensing flexibilities

Compromise agreed by the US, India, the EU and South Africa leaves trade secrets alone but approves measures that would make it faster and easier to bypass vaccine patents

05 May 2022

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

04 May 2022

Unlock unlimited access to all IAM content